Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1986 Feb;29(2):320–324. doi: 10.1128/aac.29.2.320

Pharmacokinetics and metabolism of E-5-(2-[131I]iodovinyl)-2'-deoxyuridine in dogs.

J Samuel, M J Gill, T Iwashina, D R Tovell, D L Tyrrell, E E Knaus, L I Wiebe
PMCID: PMC176399  PMID: 3717935

Abstract

E-5-(2-Iodovinyl)-2'-deoxyuridine (IVdU) is a potent inhibitor of herpes simplex virus type 1 replication in vitro. The selective antiviral activity of IVdU is due to preferential phosphorylation by the herpes simplex virus type 1-encoded thymidine kinase. This selective sequesteration provided the rationale for the development of radioiodinated IVdU as a potential radiopharmaceutical compound for use in noninvasive diagnosis of herpes simplex virus encephalitis. We studied the pharmacokinetics and the in vivo metabolism of [131I]IVdU in dogs. The radioactive components in plasma were characterized and quantitated by radio high-pressure liquid chromatography. During incubation with dog blood, [131I]IVdU was metabolized to the corresponding base (E)-5-(2-iodovinyl)uracil. 131I-labeled (E)-5-(2-iodovinyl)uracil accounted for 73% of the total radioactivity present in plasma after 2 h of incubation, suggesting that phosphorolysis of the nucleoside is the major degradation pathway of IVdU in blood. The in vivo studies showed that there was an initial rapid clearance of the tracer from blood, followed by a second very slow clearance phase. Evaluation of the renal excretion of the radiotracer showed that only 8% of the injected dose was excreted by kidneys over an 8-h period. IVdU was rapidly metabolized to three radioactive compounds. Two of these metabolites, the base (E)-5-(2-iodovinyl)uracil and iodide, were characterized. The radioactivity associated with these metabolites was responsible for the slow clearance phase. Our results suggest that the development of [131I]IVdU as a radiopharmaceutical compound will require measures to prevent its rapid degradation in vivo.

Full text

PDF
320

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allaudeen H. S., Chen M. S., Lee J. J., De Clercq E., Prusoff W. H. Incorporation of E-5-(2-halovinyl)-2'-deoxyuridines into deoxyribonucleic acids of herpes simplex virus type 1-infected cells. J Biol Chem. 1982 Jan 25;257(2):603–606. [PubMed] [Google Scholar]
  2. Allaudeen H. S., Kozarich J. W., Bertino J. R., De Clercq E. On the mechanism of selective inhibition of herpesvirus replication by (E)-5-(2-bromovinyl)-2'-deoxyuridine. Proc Natl Acad Sci U S A. 1981 May;78(5):2698–2702. doi: 10.1073/pnas.78.5.2698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Barr P. J., Oppenheimer N. J., Santi D. V. Thymidylate synthetase-catalyzed conversions of E-5-(2-bromovinyl)-2'-deoxyuridylate. J Biol Chem. 1983 Nov 25;258(22):13627–13631. [PubMed] [Google Scholar]
  4. Cheng Y. C., Dutschman G., De Clercq E., Jones A. S., Rahim S. G., Verhelst G., Walker R. T. Differential affinities of 5-(2-halogenovinyl)-2'-deoxyuridines for deoxythymidine kinases of various origins. Mol Pharmacol. 1981 Jul;20(1):230–233. [PubMed] [Google Scholar]
  5. De Clercq E. Biochemical aspects of the selective antiherpes activity of nucleoside analogues. Biochem Pharmacol. 1984 Jul 15;33(14):2159–2169. doi: 10.1016/0006-2952(84)90649-x. [DOI] [PubMed] [Google Scholar]
  6. De Clercq E., Descamps J., De Somer P., Barr P. J., Jones A. S., Walker R. T. (E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent. Proc Natl Acad Sci U S A. 1979 Jun;76(6):2947–2951. doi: 10.1073/pnas.76.6.2947. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. De Clercq E., Descamps J., Verhelst G., Walker R. T., Jones A. S., Torrence P. F., Shugar D. Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. J Infect Dis. 1980 May;141(5):563–574. doi: 10.1093/infdis/141.5.563. [DOI] [PubMed] [Google Scholar]
  8. Descamps J., De Clercq E., Barr P. J., Jones A. S., Walker R. T., Torrence P. F., Shugar D. Relative potencies of different anti-herpes agents in the topical treatment of cutaneous herpes simplex virus infection of athymic nude mice. Antimicrob Agents Chemother. 1979 Nov;16(5):680–682. doi: 10.1128/aac.16.5.680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Descamps J., De Clercq E. Specific phosphorylation of E-5-(2-iodovinyl)-2'-deoxyuridine by herpes simplex virus-infected cells. J Biol Chem. 1981 Jun 25;256(12):5973–5976. [PubMed] [Google Scholar]
  10. Desgranges C., Razaka G., Drouillet F., Bricaud H., Herdewijn P., De Clercq E. Regeneration of the antiviral drug (E)-5-(2-bromovinyl)-2'-deoxyuridine in vivo. Nucleic Acids Res. 1984 Feb 24;12(4):2081–2090. doi: 10.1093/nar/12.4.2081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Desgranges C., Razaka G., Rabaud M., Bricaud H., Balzarini J., De Clercq E. Phosphorolysis of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and other 5-substituted-2'-deoxyuridines by purified human thymidine phosphorylase and intact blood platelets. Biochem Pharmacol. 1983 Dec 1;32(23):3583–3590. doi: 10.1016/0006-2952(83)90307-6. [DOI] [PubMed] [Google Scholar]
  12. Garrett C., Wataya Y., Santi D. V. Thymidylate synthetase. Catalysis of dehalogenation of 5-bromo- and 5-iodo-2'-deoxyuridylate. Biochemistry. 1979 Jun 26;18(13):2798–2804. doi: 10.1021/bi00580a017. [DOI] [PubMed] [Google Scholar]
  13. Gill M. J., Samuel J., Wiebe L. I., Knaus E. E., Tyrrell D. L. Quantitative uptake studies of 131I-labeled (E)-5-(2-iodovinyl)-2'-deoxyuridine in herpes simplex virus-infected cells in vitro. Antimicrob Agents Chemother. 1984 Apr;25(4):476–478. doi: 10.1128/aac.25.4.476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. HAMPTON E. G., EIDINOFF M. L. Administration of 5-iododeoxyuridine-I-131 in the mouse and rat. Cancer Res. 1961 Apr;21:345–352. [PubMed] [Google Scholar]
  15. Ho S. U., Harter D. H. Herpes simplex virus encephalitis. JAMA. 1982 Jan 15;247(3):337–337. [PubMed] [Google Scholar]
  16. Maudgal P. C., Missotten L., De Clercq E., Descamps J., De Meuter E. Efficacy of (E)-5-(2-bromovinyl)-2'-deoxyuridine in the topical treatment of herpes simplex keratitis. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1981;216(4):261–268. doi: 10.1007/BF00455033. [DOI] [PubMed] [Google Scholar]
  17. Nahmias A. J., Whitley R. J., Visintine A. N., Takei Y., Alford C. A., Jr Herpes simplex virus encephalitis: laboratory evaluations and their diagnostic significance. J Infect Dis. 1982 Jun;145(6):829–836. doi: 10.1093/infdis/145.6.829. [DOI] [PubMed] [Google Scholar]
  18. PRUSOFF W. H., JAFFE J. J., GUNTHER H. Studies in the mouse of the pharmacology of 5-iododeoxyuridine, an analogue of thymidine. Biochem Pharmacol. 1960 May;3:110–121. doi: 10.1016/0006-2952(60)90027-7. [DOI] [PubMed] [Google Scholar]
  19. Samuel J., Knaus E. E., Wiebe L. I., Tyrrell D. L. Synthesis of 131I, 125I and 82Br labelled (E)-5-(2-halovinyl)-2'-deoxyuridines. Int J Appl Radiat Isot. 1984 Nov;35(11):1049–1052. doi: 10.1016/0020-708x(84)90008-5. [DOI] [PubMed] [Google Scholar]
  20. Szybalski W. X-ray sensitization by halopyrimidines. Cancer Chemother Rep. 1974 Jul-Aug;58(4):539–557. [PubMed] [Google Scholar]
  21. Whitley R. J., Soong S. J., Linneman C., Jr, Liu C., Pazin G., Alford C. A. Herpes simplex encephalitis. Clinical Assessment. JAMA. 1982 Jan 15;247(3):317–320. [PubMed] [Google Scholar]
  22. ZIMMERMAN M., SEIDENBERG J. DEOXYRIBOSYL TRANSFER. I. THYMIDINE PHOSPHORYLASE AND NUCLEOSIDE DEOXYRIBOSYLTRANSFERASE IN NORMAL AND MALIGNANT TISSUES. J Biol Chem. 1964 Aug;239:2618–2621. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES